Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease

Patients in the GEMINI 1 or 2 study (NCT00790933; Eudra CT2008‐002784‐14) with ulcerative colitis or Crohn disease had low immunogenicity rates after vedolizumab treatment for up to 52 weeks. We report immunogenicity rates from the GEMINI long‐term safety (LTS) study using a new drug‐tolerant electr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyant, Timothy, Yang, Lili, Lirio, Richard A., Rosario, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Editor's Choice: Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456828/
https://www.ncbi.nlm.nih.gov/pubmed/33908636
http://dx.doi.org/10.1002/jcph.1877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456828/
https://www.ncbi.nlm.nih.gov/pubmed/33908636
http://dx.doi.org/10.1002/jcph.1877

Ejemplares similares